论文部分内容阅读
目的：探讨银杏叶制剂（百路达）对博莱霉素A_5所致大鼠肺间质纤维化的治疗作用及机制。方法：以博莱霉素A_5所致大鼠肺间质纤维化为模型，观察百路达治疗后病理、胶原蛋白、核因子kB活性、转化生长因子-β（TGF-β）mRNA表达及蛋白水平的变化。结果：百路达治疗组肺泡炎、纤维化病变均较博莱霉素模型组减轻（P＜0．05），其胶原蛋白含量较模型组减少（P＜0．01），百路达治疗组1周肺泡巨噬细胞核因子kB（N－kB）活性明显降低（47．3％），TGF-βmRNA表达及其蛋白水平均有所降低（P＜0．05）。结论：百路达治疗肺间质纤维化确有疗效。其机制可能通过抑制核因予kB活性，减少了TGF-βmRNA表达及蛋白产生，使炎症及纤维化病变减轻。
Objective: To investigate the therapeutic effect and mechanism of Ginkgo biloba extract (Baluda) on pulmonary interstitial fibrosis in rats induced by bleomycin A_5. METHODS: Bleomycin A_5 induced pulmonary interstitial fibrosis in rats was used to observe the pathology, collagen, nuclear factor kB activity, transforming growth factor-β (TGF-β) mRNA expression, and protein expression after treatment with Balromycin. The level of change. Results: The alveolitis and fibrotic lesions in the treatment group were lower than those in the bleomycin model group (P<0.05). The collagen content was lower in the treatment group than in the model group (P<0.01). The activity of nuclear factor-kB (N-kB) in alveolar macrophages was significantly decreased (47.3%) and the expression of TGF-βmRNA and its protein levels were decreased (P<0.05). Conclusion: The treatment of Pulmonary interstitial fibrosis by Baluda is indeed effective. Its mechanism may be through inhibiting the nuclear factor kB activity, reducing TGF-β mRNA expression and protein production, and reducing inflammation and fibrotic lesions.